Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04840862 · ClinicalTrials.gov registry record · Phase 4
Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor
A Phase 4 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT04840862 is a Phase 4 study that has completed, run by University of Southern California. The registered enrollment target is 6 participants.
The verdict
NCT04840862, a Phase 4 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.
Interventions
- DRUG Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]
- DRUG Rifabutin 300mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04840862
The ClinicalTrials.gov registry entry for NCT04840862 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg] is the first listed.
NCT04840862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04840862 about?
NCT04840862 is a clinical study titled "Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor". This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.
What is the current status of trial NCT04840862?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2022-05-09. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT04840862?
The interventions under investigation include: Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg] (DRUG), Rifabutin 300mg (DRUG).
Who is sponsoring clinical trial NCT04840862?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.